15 results
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
Clinical Disease ... clinical manifestation ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Recommendations for Preventing ... amphotericin B, 3 to 5 mg/kg ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
., 4 mg/kg on days ... Leishmaniasis #Prevention ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
It is important to recognize Acute Decompensated Heart Failure (ADHF) as more than just simply a
auscultation, JVD ... ECG is vital while ... then placed on prevention ... differential #algorithm #management ... #pharmacology
Guillain-Barre Syndrome - Summary

Acute AIDP that presents with rapidly progressive flaccid weakness

Epidemiology:
 • 1-2 cases/100,000 per
meningococcal, H1N1) Clinical ... Guillain-Barre Clinical ... Treatment: • Plasmapheresis ... Syndrome #diagnosis #management ... #treatment #neurology
Myasthenia Gravis Overview

Myasthenia Gravis is an autoimmune disorder of the postsynaptic neuromuscular junction.  Ab to
Clinical Picture ... Neck: “dropping ... Serologic and EMG ... stimulation - Single fiber ... Gravis #diagnosis #management
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
other factors (e.g ... retinitis, is no longer ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Cryptococcosis in HIV-AIDS
Treatment for cryptococcosis consists of 3 phases: induction,
Recommendations for Preventing ... as substantial clinical ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Herpes Simplex Virus (HSV) Infections in HIV-AIDS
Treating Orolabial Lesions (Duration: 5–10 days)
acyclovir 5 mg/kg ... HerpesSimplex #HSV #IDSA #Prevention ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Coccidiodomycosis in HIV-AIDS
Treating Mild Infections (Such As Focal Pneumonia or asymptomatic patients
• Use until clinical ... Coccidiodomycosis #IDSA #Prevention ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology